Trial Profile

Evaluation of [18F] florbetaben in subjects participating in the Parkinson's Progression Markers Initiative (PPMI) Protocol

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 13 Jul 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Florbetaben F18 (Primary)
Indications Parkinson's disease
Focus Biomarker; Diagnostic use; Pharmacodynamics
Acronyms PPMI

Most Recent Events

08 Jun 2017 Results of longitudinal analysis of PRECEPT and PPMI trials to estimate the degree of enrichment and impact of reduced dopamine transporter (DAT) binding as a biomarker on future trials, presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
28 Apr 2016 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com